Tildrakizumab Sustains Long-Term Efficacy for Scalp Psoriasis Treatment, reveals research

Key Findings

W16 Primary Efficacy Results:

• Scalp IGA mod 2011 response rates: 49.4% for tildrakizumab compared with 7.3% for placebo.

• PSSI 90 response rates: 60.7% for tildrakizumab compared with 4.9% for placebo.

W52 Long-Term Efficacy:

• Scalp IGA mod 2011 response rates increased to 62.9% for tildrakizumab compared with 56.1% for placebo.

• PSSI 90 response rates achieved 65.2% for tildrakizumab compared with 57.3% for placebo.

Durability of Response:

• More than 80% of W16 responders to tildrakizumab were maintained at W52.

• No treatment-related serious adverse events were reported over the study period.

The study shows that in scalp psoriasis, the therapeutic efficacy of tildrakizumab has been maintained over a year of therapy. Tildrakizumab offers sustained efficacy and safety for the long-term treatment of scalp psoriasis. Therapy resulted in strong improvements in key efficacy measures, and the benefits lasted more than a year. These data position tildrakizumab as a promising option for the management of moderate-to-severe scalp psoriasis, an important area of unmet need in dermatological care.

Reference:

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. 2024 Dec 23:S0190-9622(24)03393-0. doi: 10.1016/j.jaad.2024.12.018